CLEC2D

Across TCGA pan-cancer cohorts, CLEC2D mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CLEC2D’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CLEC2D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLEC2D is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC and PDAC are the cancer types where CLEC2D tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC2D mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.274	.008	5	view →
PDAC	Male	All	−0.407	.008	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

CLEC2D–CCRCC

Open the CCRCC breakdown →